Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia-associated hypertension

Singh, Y; Samuel, VP; Dahiya, S; Gupta, G; Gillhotra, R; Mishra, A; Singh, M; SreeHarsha, N; Gubbiyappa, SK; Tambuwala, MM; Chellappan, DK; Dua, K

Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia-associated hypertension

Singh, Y Samuel, VP Dahiya, S Gupta, G Gillhotra, R Mishra, A Singh, M SreeHarsha, N Gubbiyappa, SK Tambuwala, MM Chellappan, DK Dua, K

Permalink

Publication Type:: Journal Article
Citation:: Biotechnology and Applied Biochemistry, 2019, 66 (5), pp. 715 - 719
Issue Date:: 2019-09-01

Closed Access

	Filename	Description	Size
	Singh_et_al-2019-Biotechnology_and_Applied_Biochemistry.pdf	Published Version	410.87 kB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Singh, Y	en_US
dc.contributor.author	Samuel, VP	en_US
dc.contributor.author	Dahiya, S	en_US
dc.contributor.author	Gupta, G	en_US
dc.contributor.author	Gillhotra, R	en_US
dc.contributor.author	Mishra, A	en_US
dc.contributor.author	Singh, M	en_US
dc.contributor.author	SreeHarsha, N	en_US
dc.contributor.author	Gubbiyappa, SK	en_US
dc.contributor.author	Tambuwala, MM	en_US
dc.contributor.author	Chellappan, DK	en_US
dc.contributor.author	Dua, K https://orcid.org/0000-0002-7507-1159	en_US
dc.date.available	2019-05-18	en_US
dc.date.issued	2019-09-01	en_US
dc.identifier.citation	Biotechnology and Applied Biochemistry, 2019, 66 (5), pp. 715 - 719	en_US
dc.identifier.issn	0885-4513	en_US
dc.identifier.uri	http://hdl.handle.net/10453/139290
dc.description.abstract	© 2019 International Union of Biochemistry and Molecular Biology, Inc. Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy) is a sulfur-containing amino acid of 135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If there is a higher accumulation of Hcy in the blood, that is usually above 15 µmol/L, it leads to a condition referred to as hyperhomocysteinemia. A meta-analysis of observational study suggested an elevated concentration of Hcy in blood, which is termed as the risk factors leading to ischemic heart disease and stroke. Further experimental studies stated that Hcy can lead to an increase in the proliferation of vascular smooth muscle cells and functional impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, angiotensin-converting enzyme inhibitors angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) alone are inadequate for controlling UA and creatinine level, although the addition of folic acid may be beneficial in hypertensive patients who are known to have a high prevalence of elevated Hcy. We hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia-associated hypertension.	en_US
dc.relation.ispartof	Biotechnology and Applied Biochemistry	en_US
dc.relation.isbasedon	10.1002/bab.1799	en_US
dc.subject.classification	Biotechnology	en_US
dc.subject.mesh	Humans	en_US
dc.subject.mesh	Hypertension	en_US
dc.subject.mesh	Hyperhomocysteinemia	en_US
dc.subject.mesh	Creatinine	en_US
dc.subject.mesh	Folic Acid	en_US
dc.subject.mesh	Uric Acid	en_US
dc.subject.mesh	Angiotensin Receptor Antagonists	en_US
dc.subject.mesh	Observational Studies as Topic	en_US
dc.title	Combinational effect of angiotensin receptor blocker and folic acid therapy on uric acid and creatinine level in hyperhomocysteinemia-associated hypertension	en_US
dc.type	Journal Article
utslib.citation.volume	5	en_US
utslib.citation.volume	66	en_US
utslib.for	06 Biological Sciences	en_US
utslib.for	09 Engineering	en_US
utslib.for	10 Technology	en_US
pubs.embargo.period	Not known	en_US
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Graduate School of Health
utslib.copyright.status	closed_access
pubs.issue	5	en_US
pubs.publication-status	Published	en_US
pubs.volume	66	en_US

Abstract:

© 2019 International Union of Biochemistry and Molecular Biology, Inc. Homocysteine [HSCH2CH2CH(NH2)COOH] (Hcy) is a sulfur-containing amino acid of 135.18 Da of molecular weight, generated during conversion of methionine to cysteine. If there is a higher accumulation of Hcy in the blood, that is usually above 15 µmol/L, it leads to a condition referred to as hyperhomocysteinemia. A meta-analysis of observational study suggested an elevated concentration of Hcy in blood, which is termed as the risk factors leading to ischemic heart disease and stroke. Further experimental studies stated that Hcy can lead to an increase in the proliferation of vascular smooth muscle cells and functional impairment of endothelial cells. The analyses confirmed some of the predictors for Hcy presence, such as serum uric acid (UA), systolic blood pressure, and hematocrit. However, angiotensin-converting enzyme inhibitors angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin receptor blockers (ARBs) alone are inadequate for controlling UA and creatinine level, although the addition of folic acid may be beneficial in hypertensive patients who are known to have a high prevalence of elevated Hcy. We hypothesized that combination therapy with an ARB (olmesartan) and folic acid is a promising treatment for lowering the UA and creatinine level in hyperhomocysteinemia-associated hypertension.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/139290